TY - JOUR
KW - Dulaglutide
KW - Glp-1 ra
KW - Observational study
KW - primary care
KW - Subcutaneous semaglutide
KW - Therapeutic inertia
KW - Type 2 diabetes
AU - L. von Arx
AU - J. Rachman
AU - J. Webb
AU - C. Casey
AU - A. Patel
AU - C. Diomatari
AU - R. Wood
AU - I. Idris
AD - Eli Lilly and Company, Herlev, Denmark.
Eli Lilly and Company, Basingstoke, UK.
Adelphi Real World, Bollington, UK.
University of Nottingham, Nottingham, UK.
AN - 36692268
BT - Diabetes Obes Metab
DO - 10.1111/dom.14985
DP - NLM
ET - 2023/01/25
LA - eng
N1 - 1463-1326
von Arx, Lill-Brith
Orcid: 0000-0002-7170-6268
Rachman, Jonathan
Webb, Joanne
Casey, Caroline
Patel, Amisha
Diomatari, Christina
Wood, Robert
Idris, Iskandar
Journal Article
England
Diabetes Obes Metab. 2023 Jan 24. doi: 10.1111/dom.14985.
PY - 2023
SN - 1462-8902
T2 - Diabetes Obes Metab
TI - Therapeutic inertia related to the injectable glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in patients with type 2 diabetes in UK primary care
ER -